Skip to content

Ayurvedic Management Of Fatty Liver

CLINICAL EVALUATION OF THE EFFECT ROHITAKADI YOGA AND SARVAKALPA KWATH IN NON-ALCOHOLIC FATTY LIVER DISEASE W.S.R TO YAKRITUDARA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019499
Enrollment
40
Registered
2019-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Use of RohitakaadiYoga with anupana of Sarvakalpa kwath associated with Pathyasevan and life style modification.: Rohitakaadi yoga: â?¢Dosage: 5 gms BD before food intake. â?¢Anupana:

Sponsors

Patanjali Ayurveda College
Lead Sponsor
Dr Vishala Kala
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between the age group of 18-65 years will be selected. 2. Patients irrespective of sex, religion, occupation and chronicity will be selected for the study. 3. Both fresh and treated cases would be taken for the study. 4. Patients with higher LFT levels than the upper limit of normal value will be selected. 5. Patients with GRADE 1 and GRADE 2 fatty liver will be selected for the study. 6. Patient with control Diabetes mellitus having GRADE 1 and GRADE 2 fatty liver will be selected for the study.

Exclusion criteria

Exclusion criteria: 1. Patients aged 65 years will be excluded. 2. Pregnant or lactating women will be excluded. 3. Patients who had hepatitis B, C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded. 4. Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded. 5. Patients will be excluded having decompensated liver disease. 6. Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded. 7. Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded. 8. Patients having GRADE 3 fatty liver disease will be excluded.

Design outcomes

Primary

MeasureTime frame
All investigations like SGOT, SGPT, Alkaline Phosphates, Ultrasonography Timepoint: Before intervention and follow-up at 1 month

Secondary

MeasureTime frame
All investigations like SGOT, SGPT, Alkaline Phosphates, Ultrasonography Timepoint: After intervention at 2 months

Countries

India

Contacts

Public ContactDr Abhishek Bhushan Sharma

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan, Haridwar

ayu.abhishek@gmail.com9458636020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026